Search Main Menu Main Content

Choose language
Change contrast :
Standards Reinforced

icone

HAS profile

Mission
Organisational Structure
Ethics, transparency and management of conflicts of interest

International relations and projects
Publications

Recherche

icone plus
My account

Email alert Subscription

Newsletter Subscription

My search

Refresh

Please fill in your email address to retrieve your email alerts subscriptions.

New subscription

Please fill in your email address to retrieve your newsletter subscriptions.

You do not have a saved search
No element in selection
Contact

1 result

Active substance : rifampicine
Active substance : acide nalidixique
Active substance : acide clavulanique
Active substance : tazobactam
Type : Practice guidelines

Topic

Economics and public health (1)
Plus ...
- Organisation of care (1)
Diseases and conditions (1)
Plus ...
- Infectious diseases (1)
- Plus ...
  - Bacterial infections (1)
Quality of care and patient safety (1)
Plus ...
- Quality of care and patient safety (1)

Practice Guidelines and Other Guides (1)
Plus ...
- Practice guidelines (1)

alter (1)

Français (1)

Active substance

acide clavulanique (1)
acide fusidique (1)
acide nalidixique (1)
amikacine (1)
amoxicilline (1)
ceftazidime (1)
ceftriaxone (1)
ciprofloxacine (1)
clindamycine (1)
gentamicine (1)
rifampicine (1)
tazobactam (1)
tobramycine (1)
vancomycine (1)

Première page
Page précédente
/ 1
Page suivante
Dernière page

Sorted by :Relevance

Title
Date

Antibiotic therapy and prevention of bacterial resistance in healthcare organisations

Practice guidelines - Posted on 29/05/2008

Download abstract

Add to my selection

Première page
Page précédente
/ 1
Page suivante
Dernière page
10 par pages

Advancing quality in the fields of health and social care services

Follow us :

Eunetha.eu
Pasq.eu

All our publications by topic and type

Opinions on medicines
Opinions on medical devices
INAHTA briefs

Français
English

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

9tk6QX8QJGw84mYy